b2k, nueva clasificación tras lo sucedido con SGMO y estudiar el nivel de riesgo de las empresas:
<15 = Low Risk
15 - 25 = Moderate Risk
26 - 35 = High Risk
> 35 = Very High Risk
My new Rankings:
After the SGMO setback, it has some to my attention, I needed to get my risk under control. I did my risk assessments for my companies and that lead to me shaking up the company rankings considering both the fundamentals and risks. Here is a copy of the updated rankings list. You can also reach it by the link at the top of the board.
1. ARRY - They have a world class research program that has led to the development of several breakthrough therapy drugs. They are already commercial with their Braftovi and Mektovi combination in Melanoma with data coming up in Colorectal cancer. They are heavily partnered with most of their programs. The royalties on these programs are mostly in the single digit. They do have a few wholly owned programs in the pipeline that could help drive continued growth.
Composite Risk Score = 13 which is Low Risk
2. BPMC - They have a very good research engine behind pathways. They already have 4 programs in the clinic with PDGFRa/KIT, RET, FGFR4 and ALK2. They have several others in preclinic they plan to advance to clinic over time. They have best in class data for PDGFRa D842V mutation GIST and Systemic Mastocytosis. They also have very strong data in RET with BLU-667. They offer a platform of discovery that can continue yield more pathway drugs.
Composite Risk Score = 16 which is Moderate Risk
3. ATRA - They have a powerful T cell program around allogeneic T cell therapies. Their main research has been around secondary cancers related to viral infections like Epstein Barr Virus. They have been developing a very strong program around allogeneic TCR and CAR-T programs with bi-specific CAR-T cells. This company has been quietly building a powerhouse CAR-T program. We won't see much from the early programs till later next year though. I think this offers one of the best opportunities as the science moves away from autologous therapies and more toward allogeneic and off the shelf therapies. Biggest risk here is the CEO is retiring in June which could be an issue.
Composite Risk Score = 16 which is Moderate Risk
4. FATE - They have a platform of induced pluripotent stem cells (iPSC) technology. They edit stem cells and then induce their development down a path toward T and NK cells. This offers the potential to mass produce off the shelf CAR-T and NK cell therapies. They have some current programs around memory NK cells and induced stem cells around transplant that have good data. Their iPSC program has no data yet, so its still very risky.
Composite Risk Score = 25 which is Moderate Risk
5. ZYME - They have some of the best antibody technologies in the business right now. They have two drugs in early development around HER2 with ZW-25 and ZW-49. They have 7 partners now with over $6.5 billion in milestone payments. They get mid single digit royalties on all drugs discovered with their technology. They assume no cost or risks, yet they still get a slice of the revenues.
Composite Risk Score = 27 which is High Risk
6. GLYC - They have a science platform around Selectins and Galectins. They have a primary phase 3 program in Vasso Occlusive Crisis that is partnered with Pfizer. They just started their phase 3 program for Uproleselan in AML. They have an ongoing phase 1 trial in Multiple Myeloma. They have their next drug coming into development for E-Slectin and CXCR4. This company just seems way to cheap for such large potential.
Composite Risk Score = 18 which is Moderate Risk
7. KRYS - They have a gene editing program focused around skin diseases. They are using the Herpes virus to deliver gene into the skin cells using a topical off the shelf product. Their first product is KB-103 focused on Epidermolyis Bullosa which is a very rare skin disorder. It is still very early on with only 2 patients with 2 wounds each. The CEO and COO of this company are husband and wife which adds a level of complexity to this company.
Composite Risk Score = 35 which is Very High Risk
8. ABEO - They have a great platform of gene therapies around rare genetic disorders. Their lead program is a combined gene therapy/cell therapy for a rare skin disorder in RDEB. They have 4 follow on programs around MPS IIIA, MPS IIIB, CLN1 and CLN3 diseases. They have an early stage development program around next generation viral vectors with their AIM program. We could see some data out of these vectors next year. The recent removal of the CEO puts this one on hold until we see how the new CEO works out.
Composite Risk Score = 30 which is High Risk
9. MEIP - They have a broad pipeline of science. Their lead drug is a epigentics HDAC drug partnered with Helsinn. It is in trials for AML and MDS. They would get royalties on all sales from this drug. Their ME-401 drug is a best in class PI3K delta inhibitor which has very strong data over all competitor. It also has the best in class safety profile for this class of drugs. Its still in early trials, but very promising. The PI3K market is not a very large one. They have two other early stage drugs in development.
Composite Risk Score = 27 which is High Risk
10. PIRS - They have a very interesting technology around Anticalins. These are small proteins built to work like antibodies, but at 1/8 th the size. Most antibody drugs require lengthy infusions through IV. By shrinking the size, they could open up the therapeutic potential of many antibody drugs. They have 3 partners with over $5 billion in potential milestone payments. The science is still very early, but has huge potential if it works out. So far the early data at least indicates these proteins are safe. Now we need to see their effective.
Composite Risk Score = 37 which is Very High Risk
11. SGMO - Gene Editing is starting to look like a bust. That doesn't mean all of SGMO is worthless. They still have their Cell therapy programs. They have the T cell editing around HIV which has been in the clinic for many years. They have the big CAR-T editing program with GILD with up to $3 billion in milestones and 5% royalties. They have the stem cell editing programs around Hemoglobinopathies with VRTX. Then they have the new T reg program which is still all theory right now. It does have a little bit of data in GvHD in transplants. They have the gene regulation program which is all preclinic. No data to show that gene regulation in-vivo would work any better then gene editing.
Composite Risk Score = 34 which is High Risk
12. CRSP - They have programs around ex-vivo stem cell editing and CAR-T editing. They have a Hemoglobinopathies program partnered 50/50 with VRTX for Sickle Cell and Beta Thalassemia. They only have preclinical data for these programs so far. They also have a wholly owned CAR-T cell editing program that is capable to creating triple edited off the shelf CAR-T cells. They have great potential as long as the science works out.
Composite Risk Score = 40 which is Very High Risk
13. AFMD - They have an antibody program around T cell and NK cell engagers. Most of these are tetravalent linker proteins that bind to one receptor on the tumor and then another receptor on the NK cell or T cell. Their NK cell program is all around using CD16 to drive Antibody Dependent Cellular Cytotoxicity (ADCC). The T cell program is using CD-19. They have very impressive 88% ORR with their CD-30 program in combination with checkpoint inhibitors. That rivals the response rate of Adcetris without as much toxicity.
Composite Risk Score = 35 which is High Risk
breakout de su MM50 en diario!
a esta le han dado hoy las espinacas de Popeye
ER el 26 … normalmente pediría un tercer toque al soporte del triangulo … quisiera ser precavido aquí … pero acepto como señal de compra un breakout de RSI, un breakout de esa bull flag que además implicaría breakout de la resistencia del triangulo … aceptaría también un MACD crossover por supuesto. La sigo de cerca.
Nota de BAML:
Physician survey signals continued growth for Nuplazid
Our estimates for future Nuplazid sales
We currently assume $277mn (+24% y/y) for Nuplazid PDP sales in 2019 ramping up to
$732mn in 2026. We view upcoming data from schizophrenia (ph 3 ENHANCE readout in
mid-2019) and dementia-related psychosis (ph 3 HARMONY interim readout in 2H19
and full data in 2020) could provide additional source for future revenue growth. We
maintain our Buy rating on Acadia Pharmaceuticals (ACAD) with a $27 PO.
Todo el tocho completo aquí:
sigue redondeando suelo en soporte, me sigue gustando.
Acabo de reclamar a Bankinter para que lo incorporen, no lo tienen … te pone de un mal café cuando pasan estas cosas … normalmente lo tienen en 24-48h … espero que no sea demasiado tarde, quisiera pillarla antes de romper el canal.
AKCA es una subsidiaria de IONS, y ésta tiene evento de fase 1/2 en ciernes …
Reitero este grafico semanal porque esa cuña es un potencial caramelito teniendo en cuenta esos dos martillos semanales consecutivos y sabiendo que tiene PDFA en 2 meses ...
y ahí que va AMRN …
no la he cazado porque tiene su RSI 5 min en sobrecompra desde ayer a las 21:30h … y no afloja!!!!
asi va, claro ...